MetLife Investment Management’s BioXcel Therapeutics BTAI Stock Holding History

MetLife Investment Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-616	Closed	-$65.6K	–	2903
2023 Q2	$65.6K	Hold	616	–	–	﹤0.01%	2864
2023 Q1	$184K	Hold	616	–	–	﹤0.01%	2270
2022 Q4	$212K	Hold	616	–	–	﹤0.01%	2213
2022 Q3	$116K	Hold	616	–	–	﹤0.01%	2601
2022 Q2	$130K	Hold	616	–	–	﹤0.01%	2584
2022 Q1	$206K	Buy	616 +224	+57%	+$64.9K	﹤0.01%	2340
2021 Q4	$128K	Hold	392	–	–	﹤0.01%	2317
2021 Q3	$190K	Buy	392 +84	+27%	+$36.9K	﹤0.01%	2124
2021 Q2	$143K	Hold	308	–	–	﹤0.01%	2343
2021 Q1	$213K	Hold	308	–	–	﹤0.01%	2023
2020 Q4	$227K	Hold	308	–	–	﹤0.01%	1913
2020 Q3	$214K	Hold	308	–	–	﹤0.01%	1828
2020 Q2	$261K	Buy	+308	New	+$201K	﹤0.01%	1744

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MetLife Investment Management's BTAI Position: Q3 2023 in Review

MetLife Investment Management sold out of BioXcel Therapeutics (BTAI) in Q3 2023, closing a stake of 616 shares — an estimated $65.6K sold.

MetLife Investment Management first reported a position in BTAI in Q2 2020 and held it in 13 quarters. The position peaked at $261K in Q2 2020. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2023.

MetLife Investment Management reported no remaining BioXcel Therapeutics position as of Q3 2023 after selling out during the quarter.
MetLife Investment Management sold 616 BioXcel Therapeutics shares in Q3 2023, an estimated $65.6K.
MetLife Investment Management first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 13 quarters.
MetLife Investment Management's BioXcel Therapeutics position peaked at $261K in Q2 2020.
85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.